In colon cancer and pancreatic cancer, detection of KRAS mutant subtypes is extremely useful in predicting the therapeutic efficacy of chemotherapy and in identifying patients with poor prognosis [31]. This evidence concerns the gene KRAS and malignant colon neoplasm.